GENETIC VARIATIONS IN POLYCYSTIC OVARIAN SYNDROME DISEASE

Authors

  • Jesintha Mary M Dr. MGR Educational and Research Institute University, Chennai, Tamil Nadu
  • Umashankar V Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu
  • Vijayalakshmi M Dr. MGR Educational and Research Institute University, Chennai, Tamil Nadu
  • Deecaraman M Dr. MGR Educational and Research Institute University, Chennai, Tamil Nadu

Abstract

objective: Polycystic ovary syndrome (PCOS) is one of the common endocrine disorders among women of reproductive age with a prevalence of
approximately 5-10% worldwide. PCOS is a complex genetic disorder caused by several genes and environmental factors. The aim of this study is to
provide an overview on variations in PCOS-associated genes based on underlying genetics
Methods: Detailed literature screening was performed in PubMed. Manual curation process was adopted to extract the information on PCOS,
associated genes, mechanism of association, details of the association, significance of association mentioned in the papers were carefully captured
according to the authors' interpretation of the results.
Results: The detailed literature study revealed several genes and the genetic variations in PCOS and its critical effects, such as ovarian failure, obesity,
spontaneous abortion, recurrent pregnancy loss, insulin resistance, and hyperandrogenim. The causal genetic variants were assembled at various
levels, including mutation, single nucleotide polymorphism, etc., in PCOS and the associated phenotypic effects.
Conclusion: The genetic variations play an important role in the pathogenesis of PCOS across different ethnicities, as it is associated with various other
endocrine disorders including diabetes, insulin resistance, cardiovascular diseases, hyperandrogenism, reproductive disorders, etc. The underlying
mechanism and the network help in identifying the candidate genes or biomarkers in the disease conditions.
Keywords: Polycystic ovary syndrome, Gene, Mutation, Polymorphism, Single nucleotide polymorphism.

Downloads

Download data is not yet available.

References

Dunaif A. Insulin resistance and the polycystic ovary syndrome:

Mechanism and implications for pathogenesis. Endocr Rev

;18:774-800.

Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in

polycystic ovary syndrome. Hum Reprod Update 2008;14(4):367-78.

Escobar-Morreale HF, San Millán JL. Abdominal adiposity and the

polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266-72.

Lindholm A, Andersson L, Eliasson M, Bixo M, Sundström-Poromaa I.

Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 250-255

Mary et al.

Prevalence of symptoms associated with polycystic ovary syndrome.

Int J Gynaecol Obstet 2008;102:39-43.

Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in

women with polycystic ovary syndrome: A metaanalysis. Am J Obstet

Gynecol 2011;204(6):558.e1-6.

Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric

outcome in women with polycystic ovarian syndrome. Hum Reprod

;16(2):226-9.

Jesintha Mary M, Deecaraman M, Vijayalakshmi M, Umashankar V.

A systemic review on differential regulation of genes in polycystic

ovarian syndrome disease. Int J Pharm Bio Sci 2015;6(2):(B)893-900.

Komsa-Penkova R, Golemanov G, Georgieva G, Slavov N, Popovski K,

Ivanov P, et al. Reproductive problems in women with PCOS, the

impact of PAL-1 Carriers OF 4G PAI -1 polymorphism and BMI.

Akush Ginekol (Sofiia) 2014;53(5):3-9.

Ranjzad F, Mahmoudi T, Irani Shemirani A, Mahban A, Nikzamir A,

Vahedi M, et al. A common variant in the adiponectin gene and

polycystic ovary syndrome risk. Mol Biol Rep 2012;39(3):2313-9.

Zhang W, Wei D, Sun X, Li J, Yu X, Shi Y, et al. Family-based analysis

of adiponectin gene polymorphisms in Chinese Han polycystic ovary

syndrome. Fertil Steril 2014;101(5):1419-23.

Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F,

et al. Genetic determinants of insulin action in polycystic ovary

syndrome. Exp Clin Endocrinol Diabetes 2005;113(5):275-81.

Radavelli-Bagatini S, de Oliveira IO, Ramos RB, Santos BR,

Wagner MS, Lecke SB, et al. Haplotype TGTG from SNP 45T/G and

G/T of the adiponectin gene contributes to risk of polycystic ovary

syndrome. J Endocrinol Invest 2013;36(7):497-502.

Heinonen S, Korhonen S, Helisalmi S, Koivunen R, Tapanainen J,

Hippeläinen M, et al. Associations between two single nucleotide

polymorphisms in the adiponectin gene and polycystic ovary syndrome.

Gynecol Endocrinol 2005;21(3):165-9.

Xian L, He W, Pang F, Hu Y. ADIPOQ gene polymorphisms and

susceptibility to polycystic ovary syndrome: A HuGE survey and metaanalysis.

Eur J Obstet Gynecol Reprod Biol 2012;161(2):117-24.

Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG

trinucleotide repeats in anovulatory infertility and polycystic ovaries.

J Clin Endocrinol Metab 2000;85(9):3484-8.

Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat

polymorphism and X-chromosome inactivation in Australian Caucasian

women with infertility related to polycystic ovary syndrome. J Clin

Endocrinol Metab 2002;87(1):161-5.

Möhlig M, Jürgens A, Spranger J, Hoffmann K, Weickert MO,

Schlösser HW, et al. The androgen receptor CAG repeat modifies the

impact of testosterone on insulin resistance in women with polycystic

ovary syndrome. Eur J Endocrinol 2006;155(1):127-30.

Xia Y, Che Y, Zhang X, Zhang C, Cao Y, Wang W, et al. Polymorphic

CAG repeat in the androgen receptor gene in polycystic ovary syndrome

patients. Mol Med Rep 2012;5(5):1330-4.

Lin LH, Baracat MC, Maciel GA, Soares JM Jr, Baracat EC. Androgen

receptor gene polymorphism and polycystic ovary syndrome. Int J

Gynaecol Obstet 2013;120(2):115-8.

Zhang T, Liang W, Fang M, Yu J, Ni Y, Li Z. Association of the CAG

repeat polymorphisms in androgen receptor gene with polycystic

ovary syndrome: A systemic review and meta-analysis. Gene

;524(2):161-7.

Rajender S, Carlus SJ, Bansal SK, Negi MP, Sadasivam N, Sadasivam

MN, et al. Androgen receptor CAG repeats length polymorphism

and the risk of polycystic ovarian syndrome (PCOS). PLoS One

;8(10):e75709.

Gonzalez A, Abril E, Roca A, Aragón MJ, Figueroa MJ, Velarde P,

et al. Comment: CAPN10 alleles are associated with polycystic ovary

syndrome. J Clin Endocrinol Metab 2002;87(8):3971-6.

Dasgupta S, Sirisha PV, Neelaveni K, Anuradha K, Reddy BM.

Association of CAPN10 SNPs and haplotypes with polycystic ovary

syndrome among South Indian Women. PLoS One 2012;7(2):e32192.

Gonzalez A, Abril E, Roca A, Aragón MJ, Figueroa MJ, Velarde

P, et al. Specific CAPN10 gene haplotypes influence the clinical

profile of polycystic ovary patients. J Clin Endocrinol Metab

;88(11):5529-36.

Huang M, Xiao J, Zhao X, Liu C, Chen Q. Four polymorphisms

of the CAPN 10 gene and their relationship to polycystic ovary

syndrome susceptibility: A meta-analysis. Clin Endocrinol (Oxf)

;76(3):431-8.

Shen W, Li T, Hu Y, Liu H, Song M. Calpain-10 genetic polymorphisms

and polycystic ovary syndrome risk: A meta-analysis and metaregression.

Gene 2013;531(2):426-34.

Ehrmann DA, Schwarz PE, Hara M, Tang X, Horikawa Y,

Imperial J, et al. Relationship of calpain-10 genotype to phenotypic

features of polycystic ovary syndrome. J Clin Endocrinol Metab

;87(4):1669-73.

Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S,

et al. Variation within the type 2 diabetes susceptibility gene

calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab

;87(6):2606-10.

Witchel SF, Lee PA, Suda-Hartman M, Hoffman EP. Hyperandrogenism

and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem

Mol Med 1997;62(2):151-8.

Cisternino M, Dondi E, Martinetti M, Lorini R, Salvaneschi L,

Cuccia M, et al. Exaggerated 17-hydroxyprogesterone response

to short-term adrenal stimulation and evidence for CYP21B gene

point mutations in true precocious puberty. Clin Endocrinol (Oxf)

;48(5):555-60.

Witchel SF, Aston CE. The role of heterozygosity for CYP21

in the polycystic ovary syndrome. J Pediatr Endocrinol Metab

;13 Suppl 5:1315-7.

Yarman S, Dursun A, Oguz F, Alagol F. The prevalence, molecular

analysis and HLA typing of late-onset 21-hydroxylase deficiency

in Turkish woman with hirsutism and polycystic ovary. Endocr J

;51(1):31-6.

Witchel SF, Kahsar-Miller M, Aston CE, White C, Azziz R.

Prevalence of CYP21 mutations and IRS1 variant among women with

polycystic ovary syndrome and adrenal androgen excess. Fertil Steril

;83(2):371-5.

Franks S, Gharani N, McCarthy M. Genetic abnormalities in polycystic

ovary syndrome. Ann Endocrinol (Paris) 1999;60(2):131-3.

Wang Y, Wu XK, Cao YX, Yi L, Zou Y, Qu JW, et al. Microsatellite

polymorphism of (tttta) n in the promoter of CYP11a gene in Chinese

women with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi

;85(48):3396-400.

Wang Y, Wu X, Cao Y, Yi L, Chen J. A microsatellite polymorphism

(tttta)n in the promoter of the CYP11a gene in Chinese women with

polycystic ovary syndrome. Fertil Steril 2006;86(1):223-6.

San Millán JL, Sancho J, Calvo RM, Escobar-Morreale HF. Role of the

pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a

gene in the pathogenesis of hirsutism. Fertil Steril 2001;75(4):797-802.

Tan L, Zhu G. Role of the pentanucleotide (tttta)n polymorphisms

of Cyp11alpha gene in the pathogenesis of hyperandrogenism in

Chinese women with polycystic ovary syndrome. J Huazhong Univ Sci

Technolog Med Sci 2005;25(2):212-4.

Lazaros L, Xita N, Hatzi E, Takenaka A, Kaponis A, Makrydimas G,

et al. CYP19 gene variants affect the assisted reproduction outcome

of women with polycystic ovary syndrome. Gynecol Endocrinol

;29(5):478-82.

Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH,

et al. Association of aromatase (CYP 19) gene variation with features of

hyperandrogenism in two populations of young women. Hum Reprod

;20(7):1837-43.

Xu P, Zhang XL, Xie GB, Zhang CW, Shen SM, Zhang XX, et al.

The (TTTA)n polymorphism in intron 4 of CYP19 and the polycystic

ovary syndrome risk in a Chinese population. Mol Biol Rep

;40(8):5041-7.

Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG,

Filandra FA, Tsianateli TC, et al. Polymorphism T-->C (-34 bp) of gene

CYP17 promoter in Greek patients with polycystic ovary syndrome.

Fertil Steril 1999;71(3):431-5.

Marszalek B, Lacinski M, Babych N, Capla E, Biernacka-Lukanty J,

Warenik-Szymankiewicz A, et al. Investigations on the genetic

polymorphism in the region of CYP17 gene encoding 5’-UTR in

patients with polycystic ovarian syndrome. Gynecol Endocrinol

;15(2):123-8.

Zhao SP, Tang XM, Shao DH, Dai HY, Dai SZ. Association study

between a polymorphism of aldosterone synthetase gene and the

pathogenesis of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za

Zhi 2003;38(2):94-7.

Shen W, Li T, Hu Y, Liu H, Song M. CYP1A1 gene polymorphisms and

polycystic ovary syndrome risk: A meta-analysis and meta-regression.

Genet Test Mol Biomarkers 2013;17(10):727-35.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK.

Plasminogen activator inhibitor activity: An independent risk factor for

the high miscarriage rate during pregnancy in women with polycystic

ovary syndrome. Metabolism 1999;48(12):1589-95.

Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A,

Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of

Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 250-255

Mary et al.

plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian

syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol

;150(6):793-8.

Zhao JL, Chen ZJ, Zhao YR, Zhao LX, Wang LC, Tang R, et al.

Correlation between 4G and 5G genetypes distribution of plasminogen

activator inhibitor-1 gene polymorphism in its promoter region

with polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi

;40(8):528-31

Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor

activity, 4G5G polymorphism of the plasminogen activator inhibitor 1

gene, and first-trimester miscarriage in women with polycystic ovary

syndrome. Metabolism 2006;55(3):345-52.

Sales MF, Sóter MO, Candido AL, Fernandes AP, Oliveira FR,

Ferreira AC, et al. Correlation between plasminogen activator

inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/

proinflammatory factors in polycystic ovary syndrome. Gynecol

Endocrinol 2013;29(10):936-9.

Yalamanchi SK, Sam S, Cardenas MO, Holaday LW, Urbanek M,

Dunaif A. Association of fibrillin-3 and transcription factor-7-like 2

gene variants with metabolic phenotypes in PCOS. Obesity (Silver

Spring) 2012;20(6):1273-8.

Liu B, Lv HM, Li LN, Xia L, Zhang HX, Zhang YJ, et al. Common

variants of transcription factor 7-like 2 (TCF7L2) are associated with

reduced insulin secretion in women with polycystic ovary syndrome.

Gynecol Endocrinol 2012;28(8):594-7.

Ramos RB, Wiltgen D, Spritzer PM. Polymorphisms of TCF7L2 gene

in South Brazilian women with polycystic ovary syndrome: A crosssectional

study.

Eur J Endocrinol 2013

;169(5):569-76.

Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic

ovary syndrome, the G1691A factor V Leiden mutation, and

plasminogen activator inhibitor activity: Associations with recurrent

pregnancy loss. Metabolism 2003;52(12):1627-32.

Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic

ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin,

metformin. Clin Appl Thromb Hemost 2004;10(4):323-34.

Ahmed S, Bennett ST, Huxtable SJ, Todd JA, Matthews DR, Gough SC.

INS VNTR allelic variation and dynamic insulin secretion in healthy

adult non-diabetic Caucasian subjects. Diabet Med 1999;16(11):910-7.

Vanková M, Vrbíková J, Hill M, Cinek O, Bendlová B. Association

of insulin gene VNTR polymorphism with polycystic ovary syndrome.

Ann N Y Acad Sci 2002;967:558-65.

Powell BL, Haddad L, Bennett A, Gharani N, Sovio U, Groves CJ,

et al. Analysis of multiple data sets reveals no association between

the insulin gene variable number tandem repeat element and

polycystic ovary syndrome or related traits. J Clin Endocrinol Metab

;90(5):2988-93.

Yun JH, Gu BH, Kang YB, Choi BC, Song S, Baek KH. Association

between INS-VNTR polymorphism and polycystic ovary syndrome in

a Korean population. Gynecol Endocrinol 2012;28(7):525-8.

Skrgatic L, Baldani DP, Gersak K, Cerne JZ, Ferk P, Coric M. Genetic

polymorphisms of INS, INSR and IRS-1 genes are not associated

with polycystic ovary syndrome in Croatian women. Coll Antropol

;37(1):141-6.

Vambergue A, Lautier C, Valat AS, Cortet-Rudelli C, Grigorescu F,

Dewailly D. Follow-up study of two sisters with type A syndrome of

severe insulin resistance gives a new insight into PCOS pathogenesis in

relation to puberty and pregnancy outcome: A case report. Hum Reprod

;21(5):1274-8.

Jin L, Huang HF, Jin F, Qian YL. Polymorphism in insulin receptor

gene exon 17 in women with polycystic ovary syndrome. Zhonghua Fu

Chan Ke Za Zhi 2005;40(5):323-6.

Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA,

Villanueva R, et al. A C/T single nucleotide polymorphism at the

tyrosine kinase domain of the insulin receptor gene is associated with

polycystic ovary syndrome. Fertil Steril 2002;78(6):1240-3.

Chen ZJ, Shi YH, Zhao YR, Li Y, Tang R, Zhao LX, et al. Correlation

between single nucleotide polymorphism of insulin receptor gene

with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi

;39(9):582-5.

Kashima K, Yahata T, Fujita K, Tanaka K. Polycystic ovary syndrome:

Association of a C/T single nucleotide polymorphism at tyrosine kinase

domain of insulin receptor gene with pathogenesis among lean Japanese

women. J Reprod Med 2013;58(11-12):491-6.

Jin L, Zhu XM, Luo Q, Qian Y, Jin F, Huang HF. A novel SNP at exon

of INSR is associated with decreased insulin sensitivity in Chinese

women with PCOS. Mol Hum Reprod 2006;12(3):151-5.

El Mkadem SA, Lautier C, Macari F, Molinari N, Lefèbvre P, Renard-E,

et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp

of IRS-2 in moderate-to-severe insulin resistance of women with

polycystic ovary syndrome. Diabetes 2001;50(9):2164-8.

Sir-Petermann T, Angel B, Maliqueo M, Santos JL, Riesco MV,

Toloza H, et al. Insulin secretion in women who have polycystic

ovary syndrome and carry the Gly972Arg variant of insulin

receptor substrate-1 in response to a high-glycemic or low-glycemic

carbohydrate load. Nutrition 2004;20(10):905-10.

Lin TC, Yen JM, Gong KB, Kuo TC, Ku DC, Liang SF, et al. Abnormal

glucose tolerance and insulin resistance in polycystic ovary syndrome

amongst the Taiwanese population- not correlated with insulin receptor

substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med Genet

;7:36.

Villuendas G, Botella-Carretero JI, Roldán B, Sancho J, EscobarMorreale

HF,

San Millán JL.

Polymorphisms in

the

insulin

receptor

substrate-1

(IRS-1) gene and the insulin receptor substrate-2 (IRS-2)

gene

influence

glucose

homeostasis

and

body mass index in

women

with

polycystic ovary

syndrome and non-hyperandrogenic controls.

Hum

Reprod 2005;20(11):3184-91.

Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship

of insulin receptor substrate-1 and -2 genotypes to phenotypic

features of polycystic ovary syndrome. J Clin Endocrinol Metab

;87(9):4297-300.

Kurioka H, Takahashi K, Irikoma M, Okada M, Ozaki T, Ueda T, et al.

Diagnostic difficulty in polycystic ovary syndrome due to an LH-betasubunit

variant. Eur J Endocrinol 1999;140(3):235-8.

Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN,

Rajkowa M, et al. A new contributing factor to polycystic ovary

syndrome: The genetic variant of luteinizing hormone. J Clin

Endocrinol Metab 1999;84(5):1711-5.

Rajkhowa M, Talbot JA, Jones PW, Pettersson K, Haavisto AM,

Huhtaniemi I, et al. Prevalence of an immunological LH beta-subunit

variant in a UK population of healthy women and women with

polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995;43(3):297-303.

Dasgupta S, Sirisha PV, Neelaveni K, Anuradha K, Sudhakar G,

Reddy BM. Role of luteinizing hormone ß-subunit gene variants

among South Indian women with polycystic ovary syndrome. Gene

;494(1):51-6.

Capalbo A, Sagnella F, Apa R, Fulghesu AM, Lanzone A, Morciano A,

et al. The 312N variant of the luteinizing hormone/choriogonadotropin

receptor gene (LHCGR) confers up to 2·7-fold increased risk of

polycystic ovary syndrome in a Sardinian population. Clin Endocrinol

(Oxf) 2012;77(1):113-9.

Eriksen MB, Brusgaard K, Andersen M, Tan Q, Altinok ML, Gaster M,

et al. Association of polycystic ovary syndrome susceptibility single

nucleotide polymorphism rs2479106 and PCOS in Caucasian patients

with PCOS or hirsutism as referral diagnosis. Eur J Obstet Gynecol

Reprod Biol 2012;163(1):39-42.

Mutharasan P, Galdones E, Peñalver Bernabé B, Garcia OA, Jafari N,

Shea LD, et al. Evidence for chromosome 2p16.3 polycystic ovary

syndrome susceptibility locus in affected women of European ancestry.

J Clin Endocrinol Metab 2013;98(1):E185-90.

Cui L, Zhao H, Zhang B, Qu Z, Liu J, Liang X, et al. Genotypephenotype

correlations

of PCOS susceptibility SNPs

identified

by

GWAS

in a

large

cohort

of

Han Chinese women.

Hum

Reprod

;28(2):538-44.

Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann

DA. Insulin resistance is attenuated in women with polycystic ovary

syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene.

J Clin Endocrinol Metab 2002;87(2):772-5.

Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippeläinen M,

Koivunen R, et al. Polymorphism in the peroxisome proliferatoractivated

receptor-gamma

gene in women with polycystic ovary

syndrome.

Hum Reprod 2003;18(3):540-3.

Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B,

et al. The peroxisome proliferator activated receptor gamma Pro12Ala

polymorphism is associated with a lower hirsutism score and increased

insulin sensitivity in women with polycystic ovary syndrome. Clin

Endocrinol (Oxf) 2005;62(5):573-9.

Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M.

Pro12Ala polymorphism of the peroxisome proliferator-activated

receptor-gamma gene in women with polycystic ovary syndrome.

Gynecol Endocrinol 2006;22(6):336-42.

Shaikh N, Mukherjee A, Shah N, Meherji P, Mukherjee S. Peroxisome

proliferator activated receptor gamma gene variants influence

susceptibility and insulin related traits in Indian women with polycystic

ovary syndrome. J Assist Reprod Genet 2013;30(7):913-21.

Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 250-255

Mary et al.

Orio F Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V,

et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma

polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab

;88(12):5887-92.

Tong Y, Liao WX, Roy AC, Ng SC. Absence of mutations in the coding

regions of follicle-stimulating hormone receptor gene in Singapore

Chinese women with premature ovarian failure and polycystic ovary

syndrome. Horm Metab Res 2001;33(4):221-6.

Mohiyiddeen L, Salim S, Mulugeta B, McBurney H, Newman WG,

Pemberton P, et al. PCOS and peripheral AMH levels in relation to FSH

receptor gene single nucleotide polymorphisms. Gynecol Endocrinol

;28(5):375-7.

Fu L, Zhang Z, Zhang A, Xu J, Huang X, Zheng Q, et al. Association

study between FSHR Ala307Thr and Ser680Asn variants and polycystic

ovary syndrome (PCOS) in Northern Chinese han women. J Assist

Reprod Genet 2013;30(5):717-21.

Published

01-09-2015

How to Cite

M, J. M., U. V, V. M, and D. M. “GENETIC VARIATIONS IN POLYCYSTIC OVARIAN SYNDROME DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 5, Sept. 2015, pp. 264-8, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/7498.

Issue

Section

Original Article(s)